Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.

Rolling back malaria is possible. Tools are available but they are not used. Several countries deploy, as their national malaria control treatment policy, drugs that are no longer effective. New and innovative methods of vector control, diagnosis, and treatment should be developed, and work towards development of new drugs and a vaccine should receive much greater support. But the pressing need, in the face of increasing global mortality and general lack of progress in malaria control, is research into the best methods of deploying and using existing approaches, particularly insecticide-treated mosquito nets, rapid methods of diagnosis, and artemisinin-based combination treatments. Evidence on these approaches should provide national governments and international donors with the cost-benefit information that would justify much-needed increases in global support for appropriate and effective malaria control.

[1]  A. Mills,et al.  The Gambian National Impregnated Bednet Programme: costs, consequences and net cost-effectiveness. , 1998, Social science & medicine.

[2]  Kenneth J Rothman,et al.  Fake antimalaria drugs in Cambodia. , 2001, Lancet.

[3]  J. Breman,et al.  Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. , 2001, The American journal of tropical medicine and hygiene.

[4]  C. Goodman,et al.  Cost-effectiveness of malaria control in sub-Saharan Africa , 1999, The Lancet.

[5]  E. Lagarde,et al.  Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[6]  M. Tanner,et al.  Clinical trials of malaria vaccines: progress and prospects. , 1997, Advances in parasitology.

[7]  J. Trape The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.

[8]  A. Kroeger,et al.  Insecticide-treated materials for malaria control in Latin America: to use or not to use? , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[9]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[10]  S. Bounyasong Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women. , 2001, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[11]  R. Steketee,et al.  Risk factors for anemia in young children in rural Malawi. , 1994, American Journal of Tropical Medicine and Hygiene.

[12]  C. Maung,et al.  Clinical diagnosis of malaria on the Thai-Myanmar border. , 2001, The Yale journal of biology and medicine.

[13]  S. Benatar The HIV/AIDS pandemic: a sign of instability in a complex global system. , 2002, The Journal of medicine and philosophy.

[14]  Alan D. Lopez,et al.  Evidence-Based Health Policy--Lessons from the Global Burden of Disease Study , 1996, Science.

[15]  E. Einterz,et al.  Fever in Africa: do patients know when they are hot? , 1997, The Lancet.

[16]  D. Kyle,et al.  Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand , 1996, The Lancet.

[17]  P. Olliaro,et al.  Drug development output from 1975 to 1996: what proportion for tropical diseases? , 1998, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  B. Greenwood The epidemiology of malaria. , 1997, Annals of tropical medicine and parasitology.

[19]  B. Greenwood,et al.  Malaria in 2002 , 2002, Nature.

[20]  R. Snow,et al.  Impact of Plasmodium falciparum malaria on performance and learning: review of the evidence. , 2001, The American journal of tropical medicine and hygiene.

[21]  J. Breman,et al.  The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. , 2001, The American journal of tropical medicine and hygiene.

[22]  H. Barennes,et al.  [Intrarectal administration of quinine: an early treatment for severe malaria in children?]. , 2001, Sante.

[23]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[24]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[25]  K. Marsh,et al.  Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study , 2000, The Lancet.

[26]  J. Utzinger,et al.  Efficacy and cost‐effectiveness of environmental management for malaria control , 2001, Tropical medicine & international health : TM & IH.

[27]  Stephane Proux,et al.  Fake artesunate in southeast Asia , 2001, The Lancet.

[28]  F. Cohen,et al.  The Impact of Whole Genome Sequence Data on Drug Discovery—A Malaria Case Study , 2001, Molecular medicine.

[29]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[30]  D. Kwiatkowski,et al.  The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. , 1996, The Journal of infectious diseases.

[31]  N. White,et al.  Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[32]  K. Bojang The diagnosis of Plasmodium falciparum infection in Gambian children, by field staff using the rapid, manual, ParaSight-F test. , 1999, Annals of tropical medicine and parasitology.

[33]  P. Newton,et al.  Malaria: new developments in treatment and prevention. , 1999, Annual review of medicine.

[34]  F. Cobelens,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[35]  Richard N. Price,et al.  Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.

[36]  P. Olliaro,et al.  Averting a malaria disaster , 1999, The Lancet.

[37]  S. Hoffman,et al.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. , 1998, The Journal of infectious diseases.

[38]  S. Mharakurwa,et al.  Diagnostic performance of two antigen capture tests for the diagnosis of Plasmodium falciparum malaria in Zimbabwe. , 1999, Central African Journal of Medicine.

[39]  B. F. Hall,et al.  Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. , 1999, Vaccine.

[40]  N. White,et al.  Editorial: Antimalarial drug resistance and mortality in falciparum malaria , 1999, Tropical medicine & international health : TM & IH.

[41]  D. Kaslow,et al.  Immunogenicity and In Vivo Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein-1 in Aotus Monkeys , 1995, Molecular medicine.

[42]  D. Wirth,et al.  Malaria, the submerged disease. , 1996, JAMA.

[43]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[44]  I. Bygbjerg,et al.  Malaria diagnosis and treatment under the strategy of the integrated management of childhood illness (IMCI): relevance of laboratory support from the rapid immunochromatographic tests of ICT Malaria P.f/P.v and OptiMal. , 2001, Annals of tropical medicine and parasitology.

[45]  R. Price,et al.  Drug resistant falciparum malaria: clinical consequences and strategies for prevention. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[46]  L. BenMohamed,et al.  Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3 , 2000, Nature Medicine.

[47]  K. Mendis,et al.  The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.

[48]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[49]  Patricia De la Vega,et al.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. , 2002, The Journal of infectious diseases.

[50]  C. Lengeler,et al.  Insecticide-treated bed nets and curtains for preventing malaria. , 2004, The Cochrane database of systematic reviews.

[51]  J. Simpson,et al.  Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[52]  B. Brabin,et al.  An assessment of low birthweight risk in primiparae as an indicator of malaria control in pregnancy. , 1991, International journal of epidemiology.

[53]  Pedro Romero,et al.  A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria , 1988, Nature.

[54]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[55]  C. Drakeley,et al.  Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.

[56]  P. Olliaro,et al.  A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[57]  L. Loutan,et al.  Presumptive diagnosis of malaria results in a significant risk of mistreatment of children in urban Sahel. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[58]  N. Rooijen,et al.  Human Malaria in Immunocompromised Mice An in Vivo Model to Study Defense Mechanisms against Plasmodium falciparum , 2000 .

[59]  K. Mendis,et al.  Malaria transmission-blocking vaccines—how can their development be supported? , 2000, Nature Medicine.

[60]  P. Bloland,et al.  Making malaria-treatment policy in the face of drug resistance. , 1999, Annals of tropical medicine and parasitology.

[61]  J. Sachs,et al.  The economic burden of malaria. , 2001, The American journal of tropical medicine and hygiene.

[62]  H. Wolf,et al.  Malaria and Growth , 1999 .

[63]  U. d’Alessandro,et al.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.

[64]  D. Conway,et al.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial , 2001, The Lancet.

[65]  F. Nosten,et al.  Short communication: Paracheck‐Pf®: a new, inexpensive and reliable rapid test for P. falciparum malaria , 2001, Tropical medicine & international health : TM & IH.

[66]  Irwin W. Sherman,et al.  Malaria : parasite biology, pathogenesis, and protection , 1998 .

[67]  J. Breman,et al.  The intolerable burden of malaria: a new look at the numbers. , 2001, The American journal of tropical medicine and hygiene.

[68]  T. Richie,et al.  Progress and challenges for malaria vaccines , 2002, Nature.

[69]  A. Saul,et al.  Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. , 2002, The Journal of infectious diseases.

[70]  R. Steffen,et al.  MalaQuick versus ParaSight F as a diagnostic aid in travellers' malaria. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[71]  John Luke Gallup,et al.  Geography and Economic Development , 1998 .

[72]  J. E. Hyde,et al.  Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.

[73]  T. Mutabingwa Malaria and pregnancy: epidemiology, pathophysiology and control options. , 1994, Acta tropica.

[74]  J. Derisi,et al.  DNA microarrays for malaria. , 2002, Trends in parasitology.

[75]  P. Kazembe,et al.  A study of the consequences of malarial infection in pregnant women and their infants. , 1993, Parassitologia.

[76]  P. Olliaro,et al.  Mode of action and mechanisms of resistance for antimalarial drugs. , 2001, Pharmacology & therapeutics.

[77]  P. Chiodini Non-microscopic methods for diagnosis of malaria , 1998, The Lancet.

[78]  C. Lengeler Insecticide-treated bednets and curtains for preventing malaria. , 2000, The Cochrane database of systematic reviews.

[79]  Q. Cheng,et al.  Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. , 2000, Vaccine.

[80]  L. Chitsulo,et al.  Clinical algorithm for treatment of Plasmodium falciparum malaria in children , 1996, The Lancet.

[81]  D. Kyle,et al.  Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. , 1998, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[82]  K. Marsh Malaria disaster in Africa , 1998, The Lancet.

[83]  J. Rozendaal Fake antimalaia drugs in Cambodia , 2001, The Lancet.

[84]  J J Picq,et al.  [Epidemiology of malaria]. , 1983, Soins. Pathologie tropicale.

[85]  C. Goodman,et al.  Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. , 2001, Health economics.

[86]  C. Swisher Combination therapy of malaria. , 1969, JAMA.

[87]  H. Webster,et al.  Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. , 1994, Vaccine.

[88]  C. Menéndez,et al.  The burden of malaria in pregnancy in malaria-endemic areas. , 2001, The American journal of tropical medicine and hygiene.

[89]  P. Winstanley,et al.  Modern chemotherapeutic options for malaria. , 2001, The Lancet. Infectious diseases.

[90]  R. Steketee,et al.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. , 1993, The Journal of infectious diseases.

[91]  Thomas A. Smith,et al.  A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.

[92]  Gina Brown,et al.  Implementation of the global malaria control strategy: World Health Organization. Technical Report Series 839. World Health Organization, Switzerland, 1993. 57 + v pp., Sw. fr. 10.00 — Developing Countries Sw. fr. 7.00. ISBN 92-4-120839-2 , 1994 .

[93]  P. Chiodini,et al.  Comparison of a parasite lactate dehydrogenase-based immunochromatographic antigen detection assay (OptiMAL) with microscopy for the detection of malaria parasites in human blood samples. , 1999, The American journal of tropical medicine and hygiene.

[94]  A. Thomas,et al.  Immunization with Parasite-Derived Apical Membrane Antigen 1 or Passive Immunization with a Specific Monoclonal Antibody Protects BALB/c Mice against Lethal Plasmodium yoelii yoeliiYM Blood-Stage Infection , 2000, Infection and Immunity.

[95]  J. Rozendaal Fake antimalaria drugs in Cambodia [letter] , 2001 .

[96]  K. Bojang,et al.  An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up. , 1998, Vaccine.